BioXcel Therapeutics has patented a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The method involves administering specific doses of the drug to patients with neurodegenerative or neuropsychiatric diseases, without inducing significant sedation. GlobalData’s report on BioXcel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioXcel Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. BioXcel Therapeutics's grant share as of May 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
High-dose dexmedetomidine for treating agitation without sedation
A recently granted patent (Publication Number: US11998529B2) discloses a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The method involves administering an initial dose of 60 mcg, 80 mcg, 90 mcg, 120 mcg, or 180 mcg of dexmedetomidine, followed by a second dose of 40 mcg, 60 mcg, 80 mcg, or 90 mcg after at least two hours. The treatment is specifically targeted towards subjects with persistent agitation and a corrected QT interval using Fridericia's correction method (QTcF) of less than 470 msec.
Furthermore, the patent outlines variations in dosages based on the initial dose administered, with specific combinations of initial and second doses mentioned for different scenarios. The method also considers factors such as the change in PEC score, blood pressure, and heart rate of the subject before administering the second dose. Additionally, the patent specifies that the treatment is effective for subjects with a QTcF of less than 450 msec, emphasizing the importance of monitoring this parameter throughout the treatment process. Overall, the patent provides a detailed and structured approach to utilizing dexmedetomidine in an oromucosal formulation for managing agitation in human subjects, highlighting the significance of dosage customization and patient-specific factors in achieving optimal therapeutic outcomes.
To know more about GlobalData’s detailed insights on BioXcel Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
